These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9349931)

  • 1. Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations.
    Snoeck E; Piotrovskij V; Jacqmin P; Lins RL; Van Peer A; Danhof M; Woestenborghs R; Van Gool R; Dupont AG; Heykants J
    Eur J Clin Pharmacol; 1997; 53(1):57-63. PubMed ID: 9349931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates.
    Snoeck E; Piotrovskij V; Jacqmin P; Van Peer A; Danhof M; Ver Donck K; Woestenborghs R; Van Belle H; Van Bortel L; Van Gool R; Dupont AG; Heykants J
    Br J Clin Pharmacol; 1997 Jun; 43(6):603-12. PubMed ID: 9205820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine.
    Snoeck E; Jacqmin P; Van Peer A; Danhof M; Ver Donck K; Van Belle H; Woestenborghs R; Crabbé R; Van Gool R; Dupont A; Heykants J
    Br J Clin Pharmacol; 1996 Nov; 42(5):605-13. PubMed ID: 8951192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine.
    Snoeck E; Jacqmin P; Van Peer A; Danhof M
    J Pharmacokinet Biopharm; 1999 Jun; 27(3):257-81. PubMed ID: 10728489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine.
    Snoeck E; Ver Donck K; Jacqmin P; Van Belle H; Dupont AG; Van Peer A; Danhof M
    J Pharmacol Exp Ther; 1998 Jul; 286(1):142-9. PubMed ID: 9655853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection.
    Rongen GA; Smits P; Ver Donck K; Willemsen JJ; De Abreu RA; Van Belle H; Thien T
    J Clin Invest; 1995 Feb; 95(2):658-68. PubMed ID: 7860749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium.
    Böhm M; Weinhold C; Schwinger RH; Müller-Ehmsen J; Böhm D; Reichenspurner H; Reichart B; Erdmann E
    Br J Pharmacol; 1994 May; 112(1):137-42. PubMed ID: 8032635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleoside transport inhibition and platelet aggregation in human blood: R75231 and its enantiomers, draflazine and R88016.
    Beukers MW; Kerkhof CJ; IJzerman AP; Soudijn W
    Eur J Pharmacol; 1994 Jan; 266(1):57-62. PubMed ID: 8137884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleoside transport inhibition by draflazine in unstable coronary disease.
    Andersen K; Dellborg M; Swedberg K
    Eur J Clin Pharmacol; 1996; 51(1):7-13. PubMed ID: 8880045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of a series of draflazine analogues with equilibrative nucleoside transporters: species differences and transporter subtype selectivity.
    Hammond JR
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Apr; 361(4):373-82. PubMed ID: 10763851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affinity, binding kinetics and functional characterization of draflazine analogues for human equilibrative nucleoside transporter 1 (SLC29A1).
    Vlachodimou A; Konstantinopoulou K; IJzerman AP; Heitman LH
    Biochem Pharmacol; 2020 Feb; 172():113747. PubMed ID: 31830468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics and metabolic disposition of exogenous phosphocreatine in rats].
    Zou LL; Li QS; Han GZ; Lü L; Xi H; Li JH
    Yao Xue Xue Bao; 2011 Jan; 46(1):75-80. PubMed ID: 21465812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linear pharmacokinetics of a new inotropic agent.
    Trenque T; Barre J; Lamiable D; Tillement JP
    Arzneimittelforschung; 1994 Apr; 44(4):471-3. PubMed ID: 8010998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans.
    Asai F; Jakubowski JA; Naganuma H; Brandt JT; Matsushima N; Hirota T; Freestone S; Winters KJ
    Platelets; 2006 Jun; 17(4):209-17. PubMed ID: 16769598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients.
    Hildebrand M
    Eur J Clin Pharmacol; 1997; 53(1):51-6. PubMed ID: 9349930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-grade nucleoside transport inhibition stimulates ventilation in humans.
    Rongen GA; Smits P; Bootsma G; Ver Donck K; de Vries A; Thien T
    J Clin Pharmacol; 1995 Apr; 35(4):357-61. PubMed ID: 7650223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans.
    Matsushima N; Jakubowski JA; Asai F; Naganuma H; Brandt JT; Hirota T; Freestone S; Winters KJ
    Platelets; 2006 Jun; 17(4):218-26. PubMed ID: 16769599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers.
    Wittke B; Mackie IJ; Machin SJ; Timm U; Zell M; Goggin T
    Br J Clin Pharmacol; 1999 May; 47(5):521-30. PubMed ID: 10336576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions.
    Hussein Z; Fraser IJ; Lees KR; Muir KW; Lunnon MW; Hobbiger SF; Posner J
    Br J Clin Pharmacol; 1996 Jun; 41(6):505-11. PubMed ID: 8799514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.